Week In Review: Full-Life Acquires Focus-X And Its Eight Radiotherapeutics In $245 Million Deal

Full-Life Technologies, a Brussels-Shanghai radiotherapeutics company, will acquire Focus-X Therapeutics for up to $245 million. Using its proprietary peptide engineering technology, Focus-X has built a portfolio of eight radiopharmaceuticals.